Sensible Biotechnologies
Unlocking the next generation of mRNA medicines
The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
- Website
- sensible.bio
- City
- Oxford
- Country
- United Kingdom
- YC batch
- Summer 2021
- Team
- 55 people
- Stage
- Early stage
- AI-native
- No
More Health & bio in Oxford
FinalDose
Programmable DNA drug destroying all cancers, unlocking 80% of targets
Evolvere BioSciences
Making Next-Generation Antibiotics that Outpace Bacterial Evolution
Blue Earth Therapeutics
Advancing next generation targeted radiopharmaceuticals to treat patients who have cancer.
Canos
AI-powered blood test to detect cancer in dogs (and cats soon).
Synox Therapeutics UK
At SynOx Therapeutics, we are focused on improving the lives of people living with rare diseases. Learn more.
Claim this profile
Free and instant: prove you run sensible.bio and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Sensible Biotechnologies across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with Sensible Biotechnologies's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
